Arthicare

Capsules: osteoarthritis of the I-III degree.

Ointment

osteoarthritis of the I-III degree,

gonarthrosis,

primary and secondary arthrosis,

osteoarthritis,

intervertebral osteochondrosis,

deforming osteoarthritis,

spondylosis,

the chondromalacia patella,

scapular-brachial periarthritis.

Degenerative-dystrophic diseases of the joints and spine:

osteoarthritis of stage I-III,

osteochondrosis.

Inside. Adults — 2 caps. 2-3 times a day. The course of treatment is 1-2 months. If necessary, after consultation with a doctor, a second course is possible.

Externally. The ointment is applied in a thin layer to the undamaged skin over the affected area, rubbing until absorbed for 2-3 minutes. Duration of use-from 2 weeks to 4 months.

Inside. Adults and children over 15 years of age for the first 3 weeks are prescribed 1 capsule. 3 times a day, in the following days-1 capsule. 2 times a day, regardless of food intake, washed down with a small amount of water. The recommended duration of treatment is from 3 to 6 months. If necessary, it is possible to conduct repeated courses of treatment, the duration of which is set individually.

hypersensitivity to the components of the drug,

diabetes mellitus,

bronchial asthma,

children's age,

pregnancy,

lactation period.

hypersensitivity,

severe chronic renal failure,

pregnancy,

lactation period,

age up to 15 years.

With caution: diabetes mellitus (it is recommended to periodically monitor the level of glucose in the blood, especially at the beginning of treatment), bronchial asthma, heart and / or kidney failure (when taking chondroitin, isolated cases of edema are described), hypersensitivity to seafood.

Capsules: most often-mild gastrointestinal disorders (epigastric pain, flatulence, diarrhea, constipation), dizziness, skin allergic reactions, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia, possible allergic reactions, exacerbation of bronchial asthma.

Ointment: rarely-allergic reactions to the components of the drug.

Arthicare^® it is well tolerated by patients. Possible disorders of the gastrointestinal tract (epigastric pain, flatulence, diarrhea, constipation), dizziness, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia, allergic reactions.

Cases of overdose of the drug Arthicare^® unknown. If an overdose occurs, gastric lavage and symptomatic therapy are recommended.

Cases of overdose are unknown.

Possible symptoms of an overdose of chondroitin sulfate: hemorrhagic rash, nausea, vomiting.

Treatment: gastric lavage, symptomatic therapy.

Glucosamine sulfate and chondroitin sulfate are involved in the biosynthesis of connective tissue and thus can help prevent the destruction of cartilage and stimulate tissue regeneration. They have anti-inflammatory and analgesic effects.

Glucosamine sulfate and chondroitin sulfate are aminosaccharides that are the structural basis of the cartilage of intervertebral discs and articular cartilage:

- glycosaminoglycans (mucopolysaccharides) of the intercellular matrix of cartilage, which provide the functions of elasticity and sliding of articular surfaces,

- carbohydrate groups of collagen fibers of cartilage tissue — type II (fibrillar), type VI (microfibrillar), type IX (main) and type XI (assembly), providing elasticity and strength of cartilage.

Glucosamine sulfate. The introduction of exogenous glucosamine increases the production of the cartilage matrix and provides non-specific protection against chemical damage to the cartilage. Glucosamine in the form of sulfate can serve as a precursor to hexosamine for articular cartilage, and the sulfate anion is necessary for the synthesis of glycosaminoglycans. Another possible function of glucosamine is to protect damaged cartilage from the metabolic destruction caused by NSAIDs and corticosteroids, as well as a moderate anti-inflammatory effect.

Chondroitin sulfate. Regardless of whether it is absorbed in an intact form or in the form of individual components, it serves as an additional substrate for the formation of a healthy cartilage matrix. Chondroitin sulfate and its derivatives stimulate the formation of hyaluronic acid, the synthesis of proteoglycans and type II collagen, and protect hyaluronan from enzymatic cleavage (by suppressing the activity of hyaluronidase) and from the damaging effects of free radicals. Chondroitin sulfate maintains the viscosity of the synovial fluid, stimulates the mechanisms of cartilage repair and suppresses the activity of those enzymes (elastase, hyaluronidase) that break down cartilage. Chondroitin sulfate in the treatment of osteoarthritis relieves the symptoms of this disease and reduces the need for NSAIDs.

It stimulates the regeneration of cartilage tissue. Glucosamine and chondroitin sodium sulfate are involved in the synthesis of connective tissue, helping to prevent the destruction of cartilage and stimulating tissue regeneration.

Introduction of exogenous glucosamine increases the production of the cartilage matrix and provides non-specific protection against chemical damage to the cartilage. Another possible effect of glucosamine is to protect damaged cartilage from the metabolic destruction caused by NSAIDs and corticosteroids, as well as its own moderate anti-inflammatory effect.

Chondroitin sulfate it serves as an additional substrate for the formation of a healthy cartilage matrix. It stimulates the formation of hyaluronic acid, the synthesis of proteoglycans and type II collagen, and also protects hyaluronic acid from enzymatic cleavage (by suppressing the activity of hyaluronidase), maintains the viscosity of synovial fluid, stimulates the mechanisms of cartilage repair and suppresses the activity of those enzymes that break down cartilage (elastase, hyaluronidase).

In the treatment of osteoarthritis, it relieves the symptoms of the disease and reduces the need for NSAIDs.

Glucosamine sulfate. When taken orally, the bioavailability after the" first pass " through the liver is 25%.

The fraction of glucosamine that is not metabolized or bound to plasma proteins is excreted primarily in the urine. Most of the drug found in the feces after ingestion is an unabsorbed fraction. Final T_1/2 the drug associated with plasma proteins — 68 hours.

Chondroitin sulfate. When taking chondroitin sulfate once in a dose of 0.8 g (or 2 times a day in a dose of 0.4 g), the concentration of chondroitin sulfate in the plasma increases sharply over 24 hours. Absolute bioavailability — 12%.

Low-molecular-weight chondroitin sulfate is metabolized by desulphurization.

Chondroitin sulfate is excreted in the urine. T_1/2 - 310 min.

Glucosamine

Absorption. The bioavailability of glucosamine with oral administration is 25% (the effect of the first passage through the liver).

Metabolism. After absorption of the oral dose, radioactively labeled glucosamine is first detected in the plasma and later penetrates into the tissues. The highest concentrations are found in the liver, kidneys, and articular cartilage. About 30% of the taken dose persists for a long time in the tissues of bones and muscles.

Elimination. It is mainly excreted by the kidneys in an unchanged form, partially-through the intestine. T_1/2 the preparation is 68 hours.

Chondroitin sulfate

Absorption. When taking chondroitin sulfate once in a dose of 0.8 g (or 2 times a day for 0.4 g), the plasma concentration increases for 24 hours. The absolute bioavailability is 12%.

Metabolism. It is metabolized by desulphurization.

Elimination. It is excreted by the kidneys. T_1/2 - 310 min.

• Correctors of bone and cartilage metabolism in combinations

• Tissue repair stimulator [Correctors of bone and cartilage metabolism in combinations]

It is possible to increase the effect of anticoagulants and antiplatelet agents. Increases the absorption of tetracyclines, reduces the effect of semi-synthetic penicillins. The drug is compatible with NSAIDs, painkillers and glucocorticoid drugs.

Improves the absorption of tetracyclines, reduces the effect of semi-synthetic penicillins and chloramphenicol.

The drug is compatible with NSAIDs and corticosteroids.

There is limited data on the possible interaction of glucosamine and warfarin, which may lead to an increase in INR and a risk of bleeding. Therefore, with simultaneous administration, blood clotting indicators should be monitored.